汉森制药 (002412)

Hunan Hansen Pharmaceutical Co.,Ltd.

ASZ

Tags

Investments in Financial InstitutionsHelicobacter PyloriMicro and Small Cap StocksMicro Cap Selected StocksPrivate HospitalsChinese Med. IISZSE Medicine Equal Weight IndexPharmaceutical IndexSina 100 IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexOptimized Fertility (Three-child)Huijin ConceptSME Board Composite IndexPharmaceutical & Health 100 IndexHunan 50 IndexHunan

K-Line Chart

No K-line data available

Company NameHunan Hansen Pharmaceutical Co., Ltd.
Listing Date2010-05-25
Issue Price35.8RMB
Registered Capital5032010k RMB
Legal RepresentativeLiu Zhengqing
Registered AddressNo. 2688, Yincheng Avenue, Heshan District, Yiyang City, Hunan Province
IndustryTraditional Chinese Medicine II
Main BusinessResearch, production, and sales of traditional Chinese medicine preparations for gastrointestinal diseases, orthopedic trauma diseases, and cardiovascular and cerebrovascular diseases.
Company ProfileThe company is located in Longling Industrial Park, Yincheng South Road, Yiyang City, and is a key pharmaceutical industrial enterprise in Hunan Province. Its predecessor was Hunan Yiyang Pharmaceutical Co., Ltd. The company belongs to the pharmaceutical industry. Business scope: Production and sales of granules, tablets, hard capsules, pills (honey pills, water-honey pills, water pills) (including Chinese herbal extraction), decoction paste, oral liquid, syrup, tincture, large-volume injections, small-volume injections (including hormone types), psychotropic drugs (Fenfluramine Hydrochloride Tablets), and active pharmaceutical ingredients (Diatrizoic Acid, Bismuth Subnitrate, Meglumine, Cytidine Disodium Triphosphate, Ferric Ammonium Citrate, Dried Yeast, Albendazole, Ketotifen Fumarate, Bismuth Potassium Citrate).

Stock Details

1. Key Indicators

  • Total Shares(W): 50320.00
  • Circulating A-Shares(W): 49784.50
  • Earnings Per Share(RMB): 0.1640
  • Net Assets Per Share(RMB): 4.4929
  • Operating Revenue(W RMB): 74079.39
  • Total Profit(W RMB): 11311.46
  • Net Profit Attributable to Parent(W RMB): 8252.52
  • Net Profit Growth Rate(%): -36.88
  • Weighted Return on Equity(%): 3.6900
  • Operating Cash Flow Per Share(RMB): 0.3220
  • Undistributed Profit Per Share(RMB): 2.6372
  • Capital Reserve Per Share(RMB): 0.4653

2. Main Business

The main business covers:

  • Production of traditional Chinese medicine preparations
  • Production of chemical drugs

3. Company Basic Information

  • Company Name: Hunan Hansen Pharmaceutical Co., Ltd.
  • Listing Date: 2010-05-25
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 2688 Yincheng Avenue, Heshan District, Yiyang City, Hunan Province
  • Website: www.hansenzy.com
  • Company Profile：The issuer was established through the overall change of Hansen Co., Ltd. Hansen Co., Ltd. was established on January 21, 1998, initially named Hunan Yiyang Pharmaceutical Co., Ltd., and renamed Hunan Hansen Pharmaceutical Co., Ltd. on March 2, 2000. Approved by the shareholders' meeting of Hansen Co., Ltd. on January 4, 2008, and the company's promoter meeting on January 20, 2008, the original shareholders of Hansen Co., Ltd. acted as promoters, using the net assets of 70,306,456.30 RMB audited by Lianda as of December 31, 2007, as the base, converted into 55,000,000 shares of the joint-stock company, with the remaining 15,306,456.30 RMB converted into capital reserve. On January 22, 2008, Lianda examined and verified the above capital contribution of the promoters and issued the Lianda Verification Report [2008] No. A1008, confirming that the shareholders' contributions were genuine and fully paid. On January 22, 2008, the issuer obtained the Business License with registration number 430900000005212.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hainan Hansen Holding (Limited Partnership) General Legal Person 21200.62 42.58
2 Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. General Legal Person 2426.38 4.87
3 Jinyuan Shun'an Yuanqi Flexible Allocation Hybrid Securities Investment Fund Fund 211.40 0.42
4 Goldman Sachs & Co. LLC QFII 185.50 0.37

5. Concept Sectors

  • Helicobacter Pylori
  • Hepatitis Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Financial Investment
  • Micro-cap Selection
  • Micro & Small Cap Stocks

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information